

## **[368] USING VOICE AND AI TO REVOLUTIONIZE HEALTHCARE BY DISCOVERING VOCAL BIOMARKERS**

**Daniella Perry Ziv<sup>1</sup>, <sup>1</sup> Beyond Verbal Communication Ltd**

- **Investment Rational**

A joint research performed by Mayo Clinic and Beyond Verbal uncovered a set of vocal characteristics that are independently associated with Coronary Artery Disease (CAD). The paper was published in the Mayo Clinic Proceedings journal in April 2018. Moreover, preliminary results from our Big Data study with Maccabi Healthcare will be presented in the upcoming European Cardiology Society conference.

- **Business Strategy**

In the future, we plan to provide an online cloud-based platform available via API for B2B clientele. It tech is set to improve traditional and remote healthcare services and create a novel, patient-centric approach. This approach will support the tailoring of healthcare services to individual needs – a service which is challenging for all healthcare providers to deliver today.

- **Core Technology**

Beyond Verbal is using Voice and AI to reveal Vocal Biomarkers – acoustic features indicating various health conditions. In collaboration with leading medical institutions, we perform multiple clinical trials and conduct BIG DATA projects aimed at revealing signs of cardiovascular, pulmonary, neurological and other diseases and chronic medical conditions in the voice – allowing continuous patient monitoring and predictive analytics.

- **Product Profile/Pipeline**

Over the years, our technology has greatly evolved, starting with the analysis of emotions and progressing to wellness and now health. The ability to extract vocal biomarkers in a non-intrusive manner is going to revolutionize conventional patient care. The health vertical product is yet under research is not commercialized. We invite institutions and healthcare providers to conduct joint research.

- **What's Next?**

Beyond Verbal is currently in the process of performing BIG DATA research aimed at revealing vocal biomarkers relating, among others, to CAD, hypertension, OSA, COPD and other medical conditions. These studies are being conducted in collaboration with reputable academic institutions. We raised \$14 Mil to date, going for round B in the 2<sup>nd</sup>/3<sup>rd</sup> quarter of 2018.